Updated 18 November 2020

Overview of Data Applications without a publication

The following applications for which data was provided, are not related to a publication:

  • Incidence, morbidity and mortality of CF liver disease and cirrhosis in Europe. (2018)
  • Geographic distribution of CF patients in Europe for a phase 2, multiple dose proof-of-concept, randomized, double blind, placebo controlled and dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary measures of efficacy of subcutaneously administered ELX-02 as monotherapy and in combination with XXX in cohorts of subjects with cystic fibrosis caused by nonsense mutations. (2017)
  • Geographic distribution of patients with the mutations A561E, R334W, P2015S across Europe to assess feasibility and countries to target for PI initiated trials in patients with these mutations. (2017)
  • A snapshot of the situation of CF lung transplanted patients in Europe, as part of the International Study “Cost-effectiveness of the CF Quality of Life Questionnaire (CFQ-R) in CF patients as a co-adjuvant tool in lung transplant indication”. (2013)
  • Number and percentage of CF patients in Europe who are chronically infected with Pseudomonas aeruginosa by age, to support the Pediatric Investigational Plan for inhaled levofloxacin which was in Phase 3 development in CF patients chronically infected with Pseudomonas aeruginosa. (2011) 

An overview of the publications using the Registry’s data you will find here.